A new instrument for assessing quality of life in atopic dermatitis: international development of the Quality of Life Index for Atopic Dermatitis (QoLIAD)

Whalley, Diane; McKenna, SP; Dewar, Abigail L.; Erdman, R. A. M.; Kohlmann, Thomas; Niero, Mauro; Cook, Sharon Anne; Crickx, B; Herdman, Michael; Frech, Feride; Assche, D van

doi:10.1111/j.1365-2133.2004.05783.x

Cited by 122 publications

(73 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on the answers, the first draft was obtained. By using other disease-specific scales such as the Psoriasis Quality of Life Scale (PSORIQoL), the Acne Quality of Life Scale (AQOLS) and the Atopic Dermatitis Quality of Life Scale (QoLIAD), the second draft was developed [6,7,8]. After consulting with specialists, the final draft was formed.…”

Section: Methodsmentioning

confidence: 99%

Development of a Quality of Life Scale for Vitiligo

Senol

Yücelten²,

Ay³

2013

Dermatology

View full text Add to dashboard Cite

Background: No vitiligo-specific quality of life scale exists. Objective: To develop a reliable and valid quality of life scale for vitiligo patients. Methods: The content was derived from in-depth interviews with vitiligo patients. The internal consistency, test-retest reliability and validity of the scale, VLQI (Vitiligo Life Quality Index), were evaluated. Results: Internal consistency was high with 30 patients and then with 183 patients (Cronbach's α 0.92 and 0.91). Test-retest scores were correlated (r = 0.86, p < 0.001). There was no difference between the test and retest scores (p > 0.05). VLQI was correlated with DLQI (Dermatology Life Quality Index) (r = 0.77, p < 0.001) and with the perceived severity by the patients (r = 0.57, p < 0.001). There was a significant relationship between the VLQI and the extent of the disease (p = 0.015). Factor analysis revealed six subscales. Conclusion: The VLQI is a valid and reliable instrument assessing quality of life of vitiligo patients.

show abstract

Section: Methodsmentioning

confidence: 99%

Development of a Quality of Life Scale for Vitiligo

Senol

Yücelten²,

Ay³

2013

Dermatology

View full text Add to dashboard Cite

show abstract

“…the Parents’ Index Quality of Life-Atopic Dermatitis (PIQoL-AD) [1] for patients less than 13 years or the Quality of Life Index-Atopic Dermatitis (QoLIAD) [2] for patients 13 years and above. Validated translations in French and Dutch for Belgium were used [3].…”

Section: Methodsmentioning

confidence: 99%

Belgian Observational Drug Utilization Study of Pimecrolimus Cream 1% in Routine Daily Practice in Atopic Dermatitis

Backer

Morren

Boonen³

et al. 2008

Dermatology

View full text Add to dashboard Cite

Background: For reimbursement purposes of pimecrolimus cream 1%, the Belgian authorities asked to document its consumption, its topical corticosteroid-sparing effect and quality of life within the routine clinical practice. Objectives: We aimed to address the 3 queries of the Belgian authorities. Methods: An open-label, observational, multicentre, 1-year study under drug prescription was performed. Results: A total of 416 consecutive patients were enrolled in 49 centres. The mean annual amount of prescribed pimecrolimuscream 1% per patient was 120.8 g (SD = 117.0), with an estimated consumption of 104.4 g (SD = 117.6). The median annual amount prescribed was 90.0 g [interquartile range (IQR) = 45–150] and the estimated consumption 63.6 g (IQR = 32.4–132). Topical corticosteroids had been used before the study in 81.7% of the population. With pimecrolimus cream 1% during the study, 83.3% of the previous corticosteroid users stated less topical corticosteroid use than before and 36% of them did not apply topical corticosteroids at all during the study. The mean improvements compared to baseline in Parents’ Index Quality of Life-Atopic Dermatitis and Quality of Life Index-Atopic Dermatitis scores were 34.5% (SD = 84.3) and 31.2% (SD = 70.8), respectively. The median improvements were 50.0% (IQR = 12.5–85.7%) and 46.4% (IQR = 0.0–85.0%), respectively. Conclusions: In routine practice the consumption of pimecrolimus cream 1% is relatively low, with corticosteroid-sparing effect, improvement in quality of life and good tolerability.

show abstract

“…For evaluating the life quality in AD, Quality of Life Index for Atopic Dermatitis (QoLIAD) is designed for adults with AD based on Quality of Life (QoL)and Children's Dermatology Life Quality Index (CDLQI) for children AD. These instruments could be used to evaluate the impact degree of AD and also measure the therapeutic effect (Whalley et al, 2004;BenGashir et al, 2004). Taken together, though well recognized and widely applied, the implementation of various scoring systems is complicated and subject to a variety of bias.…”

Section: Assessment Of Clinical Scoring Systemsmentioning

confidence: 99%